咖啡因治療早產(chǎn)兒呼吸暫停遠期療效評價系統(tǒng)綜述
發(fā)布時間：2018-11-22 13:45
【摘要】：目的:運用系統(tǒng)評價及Meta分析方法,比較咖啡因和安慰劑治療早產(chǎn)兒呼吸暫(apnea of prematurity,AOP)的遠期療效差別,并分析比較早期和晚期應(yīng)用咖啡因治療AOP遠期療效。方法:檢索數(shù)據(jù)庫為Pub Med、EMBASE、CNKI、WanFang Data等,時間為2000年1月至2016年6月關(guān)于咖啡因與安慰劑對比治療AOP的文獻,和早晚期對比使用咖啡因治療AOP的研究。采用改良Jadad量表進行質(zhì)量評價,對符合質(zhì)量要求的研究納入研究,使用Stata 11.0統(tǒng)計軟件進行Meta分析,合并統(tǒng)計量為RR值、OR值及95%CI。結(jié)果:共納入11個隨機對照研究,第一部分5個前瞻性隊列研究,咖啡因比安慰劑治療AOP能顯著降低認知障礙(RR=0.887,95%CI:0.813~0.966,P=0.006)、腦癱(RR=0.581,95%CI:0.437~0.774,P0.001)和動脈導(dǎo)管未閉(RR=0.598,95%CI 0.538~0.665,P=0.000)的發(fā)病率,第二部分,6個回顧性隊列研究,早期使用咖啡因能顯著減低PDA的發(fā)病率(OR=0.568,95%CI 0.362~0.892,P=0.014)和支氣管肺發(fā)育不良的發(fā)病率(OR=0.641,95%CI:0.517~0.795,P0.001)。結(jié)論:咖啡因治療AOP能有效降低早產(chǎn)兒的認知障礙、腦癱和動脈導(dǎo)管未閉(Patent ductus arteriosus,PDA)的發(fā)病率,同時在AOP的咖啡治療中,早期使用比晚期使用更有效降低PDA和支氣管肺發(fā)育不良(Bronchopulmonary dysplasia,BPD)的發(fā)病率。
[Abstract]:Objective: to compare the long-term efficacy of caffeine and placebo in the treatment of respiratory temporary (apnea of prematurity,AOP in premature infants by systematic evaluation and Meta analysis, and to compare the long-term efficacy of caffeine in the treatment of AOP in the early and late stages. Methods: the database was Pub Med,EMBASE,CNKI,WanFang Data et al., from January 2000 to June 2016, the literature on the comparative treatment of caffeine and placebo on AOP, and the study on the treatment of AOP with caffeine in the morning and evening. The modified Jadad scale was used to evaluate the quality, the research according to the quality requirements was included in the study, and the Meta analysis was carried out by using Stata 11.0 statistical software. The combined statistics were RR, OR and 95 CIs. Results: in 11 randomized controlled trials, the first part of 5 prospective cohort studies showed that caffeine significantly reduced cognitive impairment (RR=0.887,95%CI:0.813~0.966,P=0.006) compared with placebo. Incidence of cerebral palsy (RR=0.581,95%CI:0.437~0.774,P0.001) and patent ductus arteriosus (RR=0.598,95%CI 0.538 / 0.665P0.000), part II, 6 retrospective cohort studies, Early use of caffeine significantly reduced the incidence of PDA (OR=0.568,95%CI 0.362) and bronchopulmonary dysplasia (OR=0.641,95%CI:0.517~0.795,P0.001). Conclusion: caffeine treatment for AOP can effectively reduce the incidence of cognitive impairment, cerebral palsy and patent ductus arteriosus (Patent ductus arteriosus,PDA) in premature infants. Early use is more effective than late use in reducing the incidence of PDA and bronchopulmonary dysplasia (Bronchopulmonary dysplasia,BPD).
【學(xué)位授予單位】：皖南醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R722.6
本文編號：2349543
[Abstract]:Objective: to compare the long-term efficacy of caffeine and placebo in the treatment of respiratory temporary (apnea of prematurity,AOP in premature infants by systematic evaluation and Meta analysis, and to compare the long-term efficacy of caffeine in the treatment of AOP in the early and late stages. Methods: the database was Pub Med,EMBASE,CNKI,WanFang Data et al., from January 2000 to June 2016, the literature on the comparative treatment of caffeine and placebo on AOP, and the study on the treatment of AOP with caffeine in the morning and evening. The modified Jadad scale was used to evaluate the quality, the research according to the quality requirements was included in the study, and the Meta analysis was carried out by using Stata 11.0 statistical software. The combined statistics were RR, OR and 95 CIs. Results: in 11 randomized controlled trials, the first part of 5 prospective cohort studies showed that caffeine significantly reduced cognitive impairment (RR=0.887,95%CI:0.813~0.966,P=0.006) compared with placebo. Incidence of cerebral palsy (RR=0.581,95%CI:0.437~0.774,P0.001) and patent ductus arteriosus (RR=0.598,95%CI 0.538 / 0.665P0.000), part II, 6 retrospective cohort studies, Early use of caffeine significantly reduced the incidence of PDA (OR=0.568,95%CI 0.362) and bronchopulmonary dysplasia (OR=0.641,95%CI:0.517~0.795,P0.001). Conclusion: caffeine treatment for AOP can effectively reduce the incidence of cognitive impairment, cerebral palsy and patent ductus arteriosus (Patent ductus arteriosus,PDA) in premature infants. Early use is more effective than late use in reducing the incidence of PDA and bronchopulmonary dysplasia (Bronchopulmonary dysplasia,BPD).
【學(xué)位授予單位】：皖南醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R722.6
【參考文獻】
相關(guān)期刊論文 前1條
1 Hesham Abdel-Hady;Nehad Nasef;Abd Elazeez Shabaan;Islam Nour;;Caffeine therapy in preterm infants[J];World Journal of Clinical Pediatrics;2015年04期
，本文編號：2349543
本文鏈接：http://www.sikaile.net/yixuelunwen/eklw/2349543.html
最近更新
教材專著
